Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities

Pharmacological Research

Volumn 62, Issue 4, 2010, Pages 337-343

  Lin, Yinchiu ^a   Shia, Kak Shan ^a   Hsiao, Wen Chi ^a   Hsieh, Wan Ping ^a   Yeh, Teng Kuang ^a   Tseng, Shi Liang ^a   Hsu, Chia Yu ^a   Chao, Yu Sheng ^a   Hung, Ming Shiu ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Appetite; CB1 receptor; Drug metabolism; Intrinsic activity

Indexed keywords

BPR 0432; BPR 0568; BPR 0569; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CYCLIC AMP; GUANOSINE TRIPHOSPHATE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPETITE; ARTICLE; BINDING AFFINITY; CALORIC INTAKE; CONTROLLED STUDY; DRUG BINDING; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; FOOD INTAKE; HUMAN; HUMAN CELL; IC 50; LIPID DIET; LOW CARBOHYDRATE DIET; MACRONUTRIENT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; ENERGY INTAKE; MALE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; THIOPHENES;

EID: 77955278071     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.06.001     Document Type: Article

References (31)

1. Kirkham T.C. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005, 16:297-313.
2. Abel E.L. Cannabis: effects on hunger and thirst. Behav Biol 1975, 15:255-281.
3. Williams C.M., Kirkham T.C. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berlin) 1999, 143:315-317.
4. Williams C.M., Kirkham T.C. Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 2002, 71:333-340.
5. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berlin) 1997, 132:104-106.
6. Simiand J., Keane M., Keane P.E., Soubrie P. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998, 9:179-181.
7. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
8. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784.
9. Di Marzo V., Despres J.P. CB1 antagonists for obesity-what lessons have we learned from rimonabant?. Nat Rev Endocrinol 2009, 5:633-638.
10. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998, 63:PL113-PL117.
11. Verty A.N., McGregor I.S., Mallet P.E. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004, 354:217-220.
12. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
13. Lange J.H., Kruse C.G. Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today 2005, 10:693-702.
14. Lee H.K., Choi E.B., Pak C.S. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 2009, 9:482-503.
15. Tseng S.L., Hung M.S., Chang C.P., Song J.S., Tai C.L., Chiu H.H., et al. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists. J Med Chem 2008, 51:5397-5412.
16. Lin L.S., Lanza T.J., Jewell J.P., Liu P., Shah S.K., Qi H., et al. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006, 49:7584-7587.
17. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005, 76:1307-1324.
18. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
19. Vauquelin G., Van Liefde I. G protein-coupled receptors: a count of 1001 conformations. Fundam Clin Pharmacol 2005, 19:45-56.
20. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 2004, 65:2-11.
21. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:381-416.
22. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
23. Kenakin T. Differences between natural and recombinant G protein-coupled receptor systems with varying receptor/G protein stoichiometry. Trends Pharmacol Sci 1997, 18:456-464.
24. McLaughlin P.J., Winston K., Swezey L., Wisniecki A., Aberman J., Tardif D.J., et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2003, 14:583-588.
25. McLaughlin P.J., Qian L., Wood J.T., Wisniecki A., Winston K.M., Swezey L.A., et al. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 2006, 83:396-402.
26. Salamone J.D., McLaughlin P.J., Sink K., Makriyannis A., Parker L.A. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007, 91:383-388.
27. Sink K.S., McLaughlin P.J., Wood J.A., Brown C., Fan P., Vemuri V.K., et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008, 33:946-955.
28. Berry D.J., Beran R.G., Plunkeft M.J., Clarke L.A., Hung W.T. The absorption of gabapentin following high dose escalation. Seizure 2003, 12:28-36.
29. Rinaldi-Carmona M., Barth F., Congy C., Martinez S., Oustric D., Perio A., et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004, 310:905-914.
30. Ross R.A. Allosterism and cannabinoid CB(1) receptors: the shape of things to come. Trends Pharmacol Sci 2007, 28:567-572.
31. Janero D.R., Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs 2009, 14:43-65.